There is an estimated potential for a 100-fold increase in delta variant neutralization in post-dose of three compared to pre-dose of three, the researchers wrote in the data post, which is expected to be discussed Wednesday morning by Pfizer during a company earnings call.
Laboratory testing of the blood of several dozen people receiving their first dose of Pfizer and AstraZeneca vaccines inhaled the delta variant, the team reported in Nature Journal. A week after receiving their second dose of the vaccine, the researchers thought the immune boost was strong enough to neutralize delta, though it was still slightly less effective than previous versions of the virus.
The team also tested unvaccinated people who had survived seizures with the virus and found they had antibodies to all four potent delta variants. A single vaccine dose increased their antibody levels sufficiently to trigger cross-protection against the delta variant and two other mutants, found the study. In the ongoing study on the effectiveness of the third vaccine by Pfizer, antibody levels against delta were five times higher in people between 18 and 55 who took a booster dose a minimum of six months after the second vaccination.
Previously published data suggested that antibody levels against delta variant were more than five times higher in people 18 to 55 years of age who received the third dose of the vaccine than those receiving the second dose. For those who received a third dose more than six months after vaccination when the protection waned, the estimated increase in neutralizing antibody titers was up to 100 times higher among study participants with the third vaccination. Dr. Mikael Dolsten, Pfizer’s head of global medical research and development, called the new data on the third vaccine “encouraging” on Wednesday’s conference call.
On Wednesday, Pfizer shared data from the third dose of its COVID-19 vaccine, suggesting that the company has significantly improved protection against highly contagious delta variant coronavirus, which has hampered the recent increase in cases and hospitalizations in the United States. Pfizer and its partner Biontech published new safety and effectiveness data for their coronavirus vaccine yesterday, showing that protection lasts at least six months before it degrades and ends afterwards. In a press release, the companies cited recent data from Israel’s Ministry of Health, which announced that the vaccine 93 percent effective in preventing serious illness and hospitalization and is 64 percent effective in stopping breakthrough infections or infections occurring without symptoms after vaccination.
Pfizer said it would seek approval for the third dose from the U.S. Food and Drug Administration in August. In an unusual move, both the FDA and the CDC stated at the time that Americans did not need a third dose and that it was not up to the companies to decide whether additional doses were needed. Pfizer expects to seek approval next month for the new dose of its emergency vaccine.
The preliminary data released Wednesday demonstrated a potential third dose of Pfizer’s coronavirus vaccine to provide a more robust protection against the highly contagious delta variant. The company said it would apply for an exemption for a third shot. According to the company, a Delta-specific vaccine is also being investigated in clinical trials that are scheduled to begin in August.
Preliminary data released by the company on Wednesday suggested that a potential third dose of Pfizer’s coronavirus vaccine increased antibody levels against the highly contagious delta variant, the company said in its second-quarter earnings report. New data suggest that a third booster of the company’s COVID-19 vaccine could help improve protection against the delta variant of the virus, according to NBC News.
Staten Island, N.Y. – New data released Wednesday by Pfizer suggests a third dose improves protection against the most contagious coronavirus, COVID-19, against the delta variant, the dominant form of the virus in the United States. New York, N.Y. – On Wednesday- Pfizer announced that data show that the third dose of the company’s Covid-19 vaccine improves protection against the transmissible delta variant. People between the ages of 18 and 55 who received the third vaccine had five times as many antibodies as those who received two vaccinations, the company said.
The Centers for Disease Control and Prevention does not recommend booster vaccinations against the delta variant, which could trigger a wave of infections. The booster vaccine is limited to severe cases of COVID-19, said Dr. Cameron Wolfe of Duke School of Medicine. As the number of Covid 19 cases has skyrocketed among LAPD employees, most have not been vaccinated, and the data was not reviewed by experts before publication.
The booster shot boosts the immune response to all viral variants, including the delta variant, Montefiori said. He said a third dose could be beneficial for immunocompromised people. Montefiore said 40 to 50 percent of those people would respond to the vaccine.
In the current data, immunity is decreasing, but it does not show that there is a problem where your immunity is compromised, similar to the measles vaccine, where two doses are sufficient.
Pfizer used data from a study in Israel, Dr. Teng said, but the focus groups were small and made up only 35 people. They took a small number of participants, 23 of them, and divided them into groups.
Experts say, for example, that it remains unclear how antibodies levels correlate with real immunity and in what degree other parts of the immune system, such as B cell and T cell factors, are protected. Antibodies can decrease over time, and studies are underway to determine whether a booster is needed. Our health editor-in-chief, Dr. Partha Nandi, told us how much extra protection Pfizer could offer.
